HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO HTDK Medical Holdings - Policy Risk Is the Biggest Uncertainty

Hansoh Pharmaceutical (3692.HK) - Lackluster Pipeline, so Bet on SiRNA?

Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?

Jiangsu Hengrui Medicine (600276.CH)-The Deal with Cstone,the Accounting Estimate Change and Outlook

Innovent Biologics Inc (1801.HK) - The PD-1 Outlook and Other Concerns

Pre-IPO BeiGene Ltd - The Future Performance Means a Lot

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Sino Biopharmaceutical / Equity Bottom-Up

<ul>
<li>We analyzed the business performance and short-term catalyst for <a href="https://www.smartkarma.com/entities/sino-biopharmaceutical" target="_blank" data-smartkarma-citation="entities:230:1" rel="noopener">Sino Biopharmaceutical (1177 HK),</a> and investors could decide whether to take advantage of it or not.</li>
<li>We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.</li>
<li>Based on our analysis, we are conservative about the Company’s outlook at the current stage.</li>
</ul>


We analyzed the business performance and short-term catalyst for Sino Biopharmaceutical (1177 HK), and investors could decide whether to take advantage of it or not.
We also analyzed the concerns about the Company as well as our insights on the valuation of biopharmaceutical companies.
Based on our analysis, we are conservative about the Company’s outlook at the current stage.


Sino Biopharmaceutical (1177.HK) - The Business, The Concerns, The Insights on Biopharma Valuation